Search Results 431-440 of 3319 for Orf
Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes ...
The primary objective of this study is to determine the proportion of patients who have no PSA or radiographic progression as determined by RECIST 1.1 or PCWG3 ...
Clinical Trials · A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With ...
This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic ...
The aim of this study is to reveal differences between symptomatic and asymptomatic severe AS patients matched for anatomic (aortic valve area) and hemodynamic ...
About this study. The purpose of this study is to determine the effect of a single dose of an oral acute MPO inhibitor drug on resting and exercise ...
Khalili BF, Chojnacki MR, Dixit K, Gururangan K, Horbinski C, Rosenow JM, Hsieh JK, Magill ST, Tate MC, Lukas RV, Templer JW. Surgical Treatment of Brain ...
mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both arms will continue treatment until ...
The purpose of this study is to see if the use of real time ultrasound of heart muscle perfusion is a usable and effective non-invasive way to detect Coronary ...
Publications. Gallego-Navarro C, Beckermann J, Linnaus ME, Swartz HJ, Stewart S, York JM, Gassner RR, Kasal CA, Seidel AG, Wachter CJ, Kooda KJ, Rich JR, ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.